Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model01:14

Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model

The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A higher...
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative prediction of intravenous drug interactions caused by cytochromes P450 inhibitors and inducers.

British journal of clinical pharmacology·2026
Same author

Chemotherapy-free combination strategies in recurrent platinum-resistant ovarian cancer: promise, evidence and perspectives.

Translational cancer research·2025
Same author

Risk Factors for Disease Recurrence in Patients with HER2+ Early Breast Cancer and Implications for Therapy: A Narrative Review.

Oncology and therapy·2025
Same author

Frequency Coding of Multisensory Integration in the Local Field Potentials of the Medial Pulvinar.

The European journal of neuroscience·2025
Same author

Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without <i>BRCA</i> Mutation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Prognostic Value of a Joint K-PD Model With Tumor Size Dynamics and CA-125 Kinetics in Recurrent Ovarian Cancer Patients: BOLD Phase II GINECO Study.

CPT: pharmacometrics & systems pharmacology·2025

Related Experiment Video

Updated: May 16, 2026

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0
07:41

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0

Published on: June 5, 2017

Pharmacodynamic models for discrete data.

Ines Paule1, Pascal Girard, Gilles Freyer

  • 1EMR, Faculté de Médecine Lyon-sud, Université Claude Bernard Lyon, France.

Clinical Pharmacokinetics
|November 27, 2012
PubMed
Summary
This summary is machine-generated.

This study reviews statistical modeling for clinical outcomes like disease events or treatment effects. It highlights methods for analyzing discrete data to improve predictions and treatment decisions in drug development.

More Related Videos

Measuring Delay Discounting in Humans Using an Adjusting Amount Task
07:47

Measuring Delay Discounting in Humans Using an Adjusting Amount Task

Published on: January 9, 2016

Related Experiment Videos

Last Updated: May 16, 2026

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0
07:41

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0

Published on: June 5, 2017

Measuring Delay Discounting in Humans Using an Adjusting Amount Task
07:47

Measuring Delay Discounting in Humans Using an Adjusting Amount Task

Published on: January 9, 2016

Area of Science:

  • Biostatistics
  • Clinical Pharmacology
  • Pharmacodynamics

Background:

  • Clinical outcomes are frequently analyzed as discrete events, including disease progression, adverse effects, or treatment responses.
  • These outcomes can be quantified using time-to-event, event counts (rates), severity grades, or combined metrics.
  • Analyzing discrete clinical outcome data necessitates specialized statistical modeling approaches.

Purpose of the Study:

  • To review common statistical modeling techniques for categorical, count, and time-to-event data.
  • To provide examples of these models applied to pharmacodynamic data analysis.
  • To underscore the utility of modeling in identifying factors influencing clinical outcomes and informing treatment decisions.

Main Methods:

  • Review of established statistical modeling approaches for discrete data types.
  • Application examples of these models in pharmacodynamic data analysis.
  • Discussion of model-based identification and quantification of factors impacting clinical outcomes.

Main Results:

  • Common modeling structures for categorical, count, and time-to-event data are referenced.
  • Examples illustrate the application of these models in pharmacodynamic studies.
  • Modeling aids in identifying influential factors, quantifying their impact, and improving predictions.

Conclusions:

  • Statistical modeling is crucial for analyzing discrete clinical outcome data.
  • These methods enhance understanding of factors affecting outcomes, leading to better predictions and clinical decisions.
  • Modeling supports optimized individual treatments and robust drug development studies.